Explore the impact of 3D models in drug discovery and how they enhance predictive insights in pre-clinical research.

The FDA has updated the labeling for Camzyos to reduce echocardiogram monitoring requirements for patients in the maintenance phase and contraindications.

Netflix’s Adolescence offers a raw, unfiltered glimpse into the inner world of teenage boys - boys who are hurting, ...

Netflix’s Adolescence offers a raw, unfiltered glimpse into the inner world of teenage boys - boys who are hurting, ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

SaveHealth assesses the relative benefits of Zoloft vs. Lexapro, comparing their usage, effectiveness, tolerability, ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

(MEMPHIS, Tenn. – April 10, 2025) Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration (FDA) approved drugs, reducing their effectiveness.

在药物联用引发的药物相互作用问题日益凸显的背景下，研究人员开展了针对细胞色素 P450（CYP）3A4 选择性抑制剂的研究。他们通过高通量筛选等手段，发现了一系列选择性 CYP3A4 抑制剂，并揭示了其选择性抑制的机制，为设计更优的抑制剂提供了指导。